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Abstract
Purpose: Despite Kaposi’s sarcoma (KS) being the most prevalent AIDS-associated cancer in resource limited settings,
optimal treatment options remain unknown. We assessed whether bleomycin/vincristine compared to vincristine
monotherapy was associated with improved treatment outcomes for AIDS-associated KS among patients initiating
combination antiretroviral therapy (cART) in Malawi.
Methods: All patients initiating cART and chemotherapy for AIDS-related KS were identified from an electronic data system
from the HIV Lighthouse Clinic from 2002 to 2011. Treatment responses were compared between patients receiving
vincristine monotherapy and vincristine/bleomycin. Binomial regression models were implemented to assess probability of
tumor improvement for patients receiving vincristine/bleomycin compared to vincristine monotherapy after a complete
cycle of chemotherapy (9–10 months). A chi-squared test was used to compare changes in CD4 count after six months of
chemotherapy.
Results: Of 449 patients with AIDS-associated KS on chemotherapy, 94% received vincristine monotherapy and 6% received
bleomycin/vincristine. Distribution of treatment outcomes was different: 29% of patients on vincristine experienced tumor
improvement compared to 53% of patients on bleomycin/vincristine. Patients receiving bleomycin/vincristine were 2.25
(95% CI: 1.47, 3.44) times as likely to experience tumor improvement as to those on vincristine monotherapy. This value
changed little after adjustment for age and baseline CD4 count: 2.46 (95% CI: 1.57, 3.86). Change in CD4 count was similar
for patients receiving vincristine monotherapy and bleomycin/vincristine (p = 0.6).
Conclusion: Bleomycin/vincristine for the treatment of AIDS-associated KS was associated with better tumor response
compared to vincristine monotherapy without impairing CD4 count recovery. Replication in larger datasets and randomized
controlled trials is necessary.
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Introduction
Kaposi’s sarcoma (KS) is the most common HIV/AIDS
associated malignancy in sub-Saharan Africa [1]. In Malawi, KS
accounts for up to 34% of all cancers, the majority of which are
among HIV-infected persons [2]. Mortality among AIDS patients
with KS is substantially higher than that among AIDS patients
without KS [3]. Although combination antiretroviral therapy
(cART) alone is associated with improved clinical KS response,
especially among those with more limited disease [4], chemother-
apeutic agents alone or in different combinations may lead to
improved KS treatment outcomes [5].
Optimal chemotherapy regimens for the treatment of AIDS
associated KS in the cART era and in resource limited settings
remain largely unknown. Various chemotherapeutic agents have
been used for the treatment of AIDS associated KS as single
agents. Although liposomal anthracyclines, such as liposomal
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doxorubicin, have shown good tumor response and tolerability,
their relatively high cost make them unaffordable for use in sub
Saharan Africa [6]. Vincristine, an inexpensive and immune-
sparing and chemotherapy agent for KS treatment, has been used
in the region with modest KS tumor response [7].
Chemotherapeutic agents administered in combinations such as
doxorubicin, vinblastine, etoposide, and bleomycin have also been
used for KS treatment. Some of these combination regimens, such
as doxorubicin/bleomycin/vincristine (ABV), have been associat-
ed with better tumor response than single agents [8–9]. However,
such combination chemotherapy regimens are associated with
severe myelosuppression. In a group of patients who already may
be immunosuppressed from HIV disease, further use of an
immunosuppressive regimen for KS disease may predispose
patients to increased risk of opportunistic infections. Consequently,
new low-cost combination regimens must be studied with a view to
reducing adverse effects, particularly immunosuppression, while
maintaining overall efficacy.
Bleomycin/vincristine is one possible combination regimen for
resource-limited settings that has never been assessed in the cART
era. Bleomycin/vincristine regimen is associated with the least
marrow toxicity and has been shown to be an effective regimen in
a patient population that has suboptimal marrow function.
Additionally, its relative low cost and ease of preparation and
administration makes it an attractive option for KS treatment in
resource-limited settings [6,10]. However, direct comparison
between bleomycin/vincristine and vincristine only regimen has
not been made for effectiveness and immune response.
Vincristine monotherapy has been the mainstay of KS
treatment since the inception of the Malawi cART program.
However, given perceived sub-optimal treatment outcomes among
this population, the Lighthouse Trust adopted a new chemother-
apy program including bleomycin/vincristine as initial therapy for
advanced disease. Within this program, we investigate if bleomy-
cin/vincristine combination chemotherapy is associated with
improved tumor outcomes compared to vincristine monotherapy
among KS patients on cART in Lilongwe, Malawi. We also
explore whether CD4 count recovery is impaired when comparing




The study was conducted at the HIV Lighthouse Clinic at
Kamuzu Central Hospital in Lilongwe, Malawi. The clinic has
been treating HIV-infected KS patients with vincristine chemo-
therapy since opening in 2002. Bleomycin became available
periodically from 2002–2011, with greater availability after 2009.
Its use was restricted to patients with advanced KS disease.
Patients on vincristine monotherapy were scheduled to receive
2 mg of vincristine administered once a week for six weeks, then
2 mg every 2 weeks for 12 weeks, then 2 mg every four weeks for
24 weeks, for a total of 18 doses over 42 weeks. Patients on
bleomycin/vincristine were given 15 units/m2 of bleomycin and
2 mg of vincristine intravenously every two weeks until the
maximum cumulative dose of bleomycin (300 units) was reached,
typically at 40 weeks.
All patients with HIV/AIDS-associated KS were in WHO stage
IV and eligible for HIV treatment, as per Malawi HIV treatment
guidelines [11]. All patients were started with the clinic’s standard
of care first-line cART regimen which consisted of stavudine/
lamuvidine/nevirapine. Initiation of chemotherapy typically coin-
cided with initiation of cART.
Study population and design
Study participants were all HIV-infected patients with advanced
KS initiating treatment for both HIV and KS at Lighthouse clinic
from July 2002 to December 2011. These patients were identified
through the electronic data system (EDS) used for routine
monitoring of HIV/AIDS program. Specifically, we screened
the entire database for those patients with KS disease and
generated a list of patient identification numbers. From this list we
verified eligibility. Patients were included in this analysis if the
patient chart could be located, if the KS status was confirmed, and
treatment regimen information was available. The analysis was
restricted to those patients with advanced KS disease stage because
these were the only patients eligible for bleomycin/vincristine
when both of these drugs become available. KS disease stage was
graded as limited stage (T-0) and advanced stage (T-1), based on
the AIDS Clinical Trial Group (ACTG) KS staging criteria
[12,13]
We conducted a retrospective cohort analysis of these patients.
The primary comparison of interest was tumor improvement at
the completion of their KS treatment, typically at 40–42 weeks.
We also compared adherence to the chemotherapy regimen and
change in CD4 count at six months from KS treatment initiation.
Data collection and management
In addition to being routinely monitored through the EDS, all
patients undergoing KS treatment have two separate paper charts.
The first one is specifically for their KS disease management and
describes doses given or missed at each visit as well as KS
treatment response. Additional information about KS treatment
was completed in a primary master file for the patient used for
general management of their HIV disease. Both of these paper
charts were completed by trained clinicians. We created a dataset
by linking these three sources as identified by a file number.
Baseline characteristics of KS patients including age, sex, and
CD4 count were obtained from the clinic EDS. CD4 count at six
months was also obtained from the EDS. KS disease stage,
treatment response, and number and dates of chemotherapy were
obtained from the KS paper chart. The primary master files
included additional information including location, size or extent
of lesions. An independent reviewer, with extensive training and
clinical experience in KS, abstracted the aforementioned variables
from the three data sources and created a single dataset linking
records with a unique identifier. All data were then analyzed using
Stata 12.
Study outcomes
The primary outcome variable was treatment response.
Treatment response was graded as complete, partial, stable, or
progressive based on the best available description of the lesions
before and after treatment as obtained from the two paper patient
charts. Complete response was defined as clearance of all Kaposi’s
sarcoma lesions for more than one month with no record of new
lesions developing. Partial response was defined as a decrease by
more than half in the size of initial lesions as reported by the
clinician assessment. Stable disease was defined as tumor response
with no noticeable increase or decrease in tumor burden or change
in functionality. Progressive disease was defined as an increase in
the size or number of Kaposi’s sarcoma lesions. Patients who died
while on treatment for their KS had their treatment outcome
classified as dead. Patients who failed to attend up to three
consecutive scheduled KS clinic visits or could not be traced were
classified as defaulters. In most cases, treatment response was
recorded for each patient either in the KS treatment charts or in
the master file. However, in some cases, we could not determine
Treatment Outcomes of Kaposi’s Sarcoma
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the treatment outcome after treatment completion because the
result was not indicated in the patient’s KS treatment chart or the
master file. These outcomes were therefore labeled missing.
For some analyses tumor response was dichotomized into
improvement or non-improvement. Tumor improvement includ-
ed complete and partial response. The tumor non-improvement
definition varied in the main and sensitivity analyses. In the main
analysis, we compared patients with complete or partial response
to patients with stable response, progressive response, or death. In
this analysis all patients who defaulted or had missing outcomes
were excluded. To explore whether those who defaulted or had
missing outcomes were biasing the effect estimates, we conducted
two additional outcome dichotomizations. In the first we
compared patients with a complete or partial response to patients
with a stable or progressive response, death, or default. Including
defaulters in this way presumed they were more likely to have poor
outcomes, something that has been documented in this setting
[13–15]. Finally, we compared patients with a complete or partial
response to all other patients, including defaulters and those with a
missing response.
To assess whether chemotherapeutic regimen was associated
with impaired CD4 count response, we compared change in CD4
count between the two different regimens after 6 months of cART
and chemotherapy treatments.
To document adherence to treatment protocol, we calculated
the proportion of completed doses per cycle of chemotherapy for
each regimen. For patients on vincristine, we used 18 as the
expected number of doses. For patients on bleomycin/vincristine,
we used 15 as the expected number of doses, even though some
patients on this treatment regimen were meant to receive fewer
doses due to their larger body surface area which would make
them reach the maximum tolerable dose earlier. However, this
was a rare occurrence, 3.6% of patients on this regimen. The total
number of doses received was expressed as a proportion of the
expected number of doses.
Data analysis
Descriptive statistics were calculated based on treatment
regimens at the time of chemotherapy initiation. We used a
Fisher’s exact test to compare proportions between the two
treatment regimens. We then compared tumor improvement
measured at the end of chemotherapy (40–42 weeks). The
distribution of the six possible treatment responses was compared:
complete, partial, stable, or progressive response, death and
default/lost to follow up. Two secondary outcomes were also
compared at 6 months: change in CD4 count and proportion of
chemotherapy doses taken. Proportions of participants in each
category were evaluated using Fisher’s Exact tests.
Unadjusted and adjusted regression analyses were then
conducted by comparing vincristine/bleomycin and vincristine
monotherapy on the probability of tumor improvement at the end
of chemotherapy. In adjusted and unadjusted regression analyses,
we fitted a generalized linear model to the data using a log link and
binomial distribution. The covariates adjusted for in multivariate
analysis were age and baseline CD4 count.
Ethical approval
The use of Lighthouse data for these analyses was approved by
the Malawi National Health Science and Research Committee
and the School of Medicine Institutional Review Board at the
University of North Carolina at Chapel Hill Protection of Human
Subjects committee. In addition, all patient records that were used
in this study were anonymised and de-identified prior to analysis.
Results
In the EDS, there were 1061 patient file numbers that indicated
the presence of KS. Some (N = 88, 8%) had no evidence of KS
after chart reviews and were excluded. For many others (N = 420,
40%) patient characteristics in the EDS, such as name, age, and
gender did not match patient characteristics in the patient master
file. These discrepancies were due to recycling of patient numbers.
When a patient died or transferred out, their number was
reassigned to another patient. These patients were also excluded as
we did not have sufficient treatment information for analysis. Of
the 1061 patient files, 553 (52%) were verified as having KS in the
patient master file. Of the 553 patients, some had indeterminate or
T-0 KS stage at baseline and were excluded. There were 449
patients (81%) with T-1 stage KS included in the analysis.
Of these 449 patients, 94% received vincristine monotherapy
and 6% received bleomycin/vincristine during the period under
study. The patient population was predominantly male (64%) and
less than 40 years of age (73%) [Table 1]. Patients receiving
vincristine monotherapy were more likely to have a CD4 count of
more than 200 cells/mL than patients on bleomycin/vincristine
(48% versus 19%, p = 0.04). Patients presenting for care in earlier
years were more likely to receive vincristine only as bleomycin was
not routinely available until later in the study period.
Overall, the distribution of the six responses was different
between the two groups (p,0.001) [Table 2]. The proportion of
patients achieving improved tumor response (partial or complete)
among those on bleomycin/vincristine was higher than those on
vincristine monotherapy (53% versus 29%). Nearly all patients
with tumor improvement on both regimens (98%) exhibited only a
partial response [Table 2]. A higher proportion of patients on
vincristine (25%) experienced tumor progression compared to
patients on bleomycin/vincristine (6%), but a higher proportion of
deaths was observed among those on bleomycin/vincristine (12%)
compared to those on vincristine (1%). Default was more common
among those on bleomycin/vincristine (18%) compared to those
on vincristine (1%). A missing response in the KS chart was also
more common among those on bleomycin/vincristine (39%)
compared to those on vincristine (20%).
There was no notable difference in CD4 count change after 6
months of chemotherapy treatment (p = 0.6) [Table 2]. All patients
on bleomycin/vincristine had CD4 count improvement (100%)
compared to 83% on vincristine only. However, the majority of
patients in both treatment regimens had missing change in CD4
count values.
There were small differences between groups in the proportion
adhering to ,50% of doses, 50–74% of doses, 75–99% of doses
and 100% of doses, with a trend towards better adherence among
those on vincristine (p = 0.2). Patients on bleomycin/vincristine
were more likely to receive less than half of the expected number
of doses than those on vincristine monotherapy regimen (46%
versus 30%). And fewer patients on bleomycin/vincristine than on
vincristine monotherapy achieved 100% adherence (27% versus
34%).
In the main unadjusted analysis, the probability of tumor
improvement was 2.25 times greater among those on bleomycin/
vincristine than among those on vincristine alone (95% CI: 1.47–
3.44) (Table 3). After adjustment for age and baseline CD4 count,
the probability of tumor improvement was 2.46 times greater
(95% CI: 1.57–3.86).
In the above models, tumor non-improvement was limited to
those with stable or progressive KS disease, or death and those
who defaulted or missing was excluded. When tumor non-
improvement was expanded to include those who defaulted the
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Table 1. Baseline characteristics.
Characteristics Vincristine (N = 421) Vincristine/Bleomycin (N = 28) Fisher’s Exact Test p-value
Sex
Female 151 36% 11 39%
Male 270 64% 17 61% 0.7
Age (Years)
, = 29 111 26% 7 25%
30–39 201 48% 11 39%
40–49 75 18% 8 29%
. = 50 34 8% 2 7% 0.6
Baseline CD4 (Cells/mL)
,200 147 53% 13 81% 0.04
.200 133 48% 3 19%
missing 141 12
Year of ART initiation
#2006 176 42% 3 11%
2007 54 13% 2 7%
2008 48 11% 2 7%
2009 50 12% 4 14%
2010 52 12% 6 21%
2011 41 10% 11 39% ,0.001
Table 2. Outcomes by treatment type*.
Vincristine Vincristine/Bleomycin Fisher’s Exact Test
N % N % p-value
Tumor Response
Complete 2 1% 0 0%
Partial 93 28% 9 53%
Stable 149 44% 2 12%
Progressive 85 25% 1 6%
Dead 3 1% 2 12%
Default/Lost 5 1% 3 18% ,0.001
Missing 84 11
Change in CD4(Cells/mL)
Decreased 32 17% 0 0%
Increased 0–100 55 30% 2 50%
Increased .100 99 53% 2 50% 0.6
Missing 235 24
Doses Received
#50% 120 30% 12 46%
50–74% 103 26% 3 12%
75%–99% 42 10% 4 15%
$100% 137 34% 7 27% 0.2
Missing 19 2
*Comparison of populations on vincristine to that on bleomycin/vincristine for tumor response, change in CD4 count, and adherence rates.
doi:10.1371/journal.pone.0091020.t002
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probability of tumor improvement was 1.88 times greater among
those on bleomycin/vincristine compared to those on vincristine
monotherapy (95% CI = 1.16–2.03) in adjusted analysis. When
tumor non-improvement was further expanded to also include
those with missing responses the probability of tumor improve-
ment was 1.48 times greater among those on bleomycin/
vincristine compared to those on vincristine monotherapy (95%
CI = 0.85–2.60) in adjusted analysis.
Discussion
Among patients with AIDS-associated KS, the probability of
tumor improvement over a 40–42 week period was more than two
times higher among those treated with bleomycin/vincristine
compared to those treated with vincristine monotherapy. Fifty
three percent of patients on bleomycin/vincristine experienced
tumor improvement, compared to only 29% of those on
vincristine monotherapy. This greater probability of tumor
improvement was seen without any noted impairment in CD4
count recovery.
This is the first direct comparison of the effectiveness of
bleomycin/vincristine and vincristine monotherapy. In other
assessments in sub Saharan Africa and elsewhere, tumor
improvement has been estimated at 57%–72% among bleomy-
cin/vincristine patients [16–18] and about 60% among vincristine
monotherapy patients [19]. Based on indirect comparisons in
separate populations [18–22], these regimens appeared to have
comparable effectiveness. However, our direct comparison in a
single population shows that dual therapy is likely more effective.
As this observational study was conducted under routine ART
program conditions, our findings represent a realistic reflection of
effectiveness for AIDS patients with KS and the results may be
generalizable to other routine settings in resource-constrained
environments.
There is an important consideration with respect to generaliz-
ability. We were unable to access patient files for almost all KS
patients who had died. This was due to a decision to reassign the
patient numbers of these deceased and transferred KS patients to
new patients. Consequently, what we measured were treatment
responses among a subset of patients with advanced disease who
generally survived, rather than the whole population of KS
patients. Future research must assess whether dual therapy has
benefits on survival in addition to benefits for morbidity.
Due to the observational nature of the work, there were some
important differences between the two patient populations at
baseline and over time. The patients receiving bleomycin/
vincristine were more likely to have lower CD4 counts but had
comparable chemotherapy adherence to those patients on
vincristine monotherapy. Based on these factors, we would expect
tumor improvement to be worse among these sicker, more
immunosuppressed patients. Nonetheless, in adjusted analysis
accounting for age and baseline CD4 count, those on bleomycin/
vincristine were 2.5 times more likely to experience tumor
improvement than those on vincristine monotherapy. Although
we believe we accounted for important potential confounders,
replicating this work in a randomized setting would strengthen the
credibility to these findings.
Our sensitivity analyses suggest the primary effect estimate may
be exaggerated. In sub-Saharan Africa, death or other adverse
outcomes are likely to account for a substantial fraction of cART
patients who are lost to follow-up [23–25]. When we assumed that
all defaulters in this population had adverse outcomes, the
probability of tumor improvement was still elevated (RR = 1.9)
among those on bleomycin/vincristine compared to those on
vincristine alone. When we assumed that both defaulters and
patients with missing outcome information had adverse outcomes,
the effect estimate still showed a trend in the same direction,
though it was less extreme (RR = 1.5). Thus it is possible that this
may have biased our primary analysis towards better treatment
outcomes in the bleomycin/vincristine group.
CD4 count recovery among patients receiving bleomycin/
vincristine was similar to recovery among those receiving
vincristine monotherapy after 6 months of chemotherapy,
suggesting the dual regimen did not lead to immunosuppression.
Since KS is essentially a disease of underlying immunosuppression,
it is not surprising that improved KS would occur in tandem with
CD4 count improvement [26]. A treatment regimen that shows
good tumor response without undue suppression of CD4 count is
an ideal option for the treatment of AIDS related KS [27].
However, these findings need to be interpreted cautiously, as the
majority of patients in our study did not have CD4 count results at
six months. Additional research in a larger population where CD4
Table 3. A Comparison of Bleomycin/Vincristine versus Vincristine Monotherapy on the Probability of Tumor Improvement at 40–
42 Weeks*.
Risk Ratio 95% Confidence Interval
A. Comparison of Tumor Improvement versus non-improvement (stable, progressive) (N = 346)
Unadjusted 2.25 (1.47, 3.44)
Adjusted 2.46 (1.57, 3.86)
B. Comparison of tumor improvement versus non-improvement (stable, progressive, dead, default) (N = 354)
Unadjusted 1.88 (1.16, 3.03)
Adjusted 2.06 (1.24, 3.41)
C. Comparison of tumor improvement versus non-improvement (stable, progressive, dead, default, missing) (N = 449)
Unadjusted 1.42 (0.81, 2.51)
Adjusted 1.48 (0.85, 2.60)
*Comparison of the probability of tumor improvement versus tumor non-improvement among patients on Bleomycin/Vincristine versus those on Vincristine
monotherapy. In model (A), only patients with recorded tumor information are included. In model (B), all patients who were dead or lost/defaulted were also included
and categorized with tumor non-improvement. In model C, all patients who were dead, lost/defaulted, or missing were classified as having tumor non-improvement. All
adjusted models control for age and baseline CD4 count.
doi:10.1371/journal.pone.0091020.t003
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count is collected routinely is needed to confirm these preliminary
observations.
Chemotherapy adherence rates were suboptimal among
patients in both groups, but slightly lower among patients on
bleomycin/vincristine than those on vincristine monotherapy.
This finding likely reflects two phenomena. First, more frequent
shortages of bleomycin rather than patient characteristics may
have undermined adherence to the bleomycin/vincristine regi-
men. Secondly, some larger patients due to their higher body
surface area may have completed their full regimen in a shorter
period of time, making them appear non-adherent. When
‘‘adherent’’ was categorized as $75%, both groups were 42–
45% adherent. Given the limitations of our data collection, we
could not fully explore all of the different patterns of adherence
timing and how they affected the outcome. However, understand-
ing the optimal timing and dosing of bleomycin/vincristine
regimen is an important area for future research.
Although a large fraction of patients had tumor improvement,
very few (N = 4) had complete tumor improvement. This is in
agreement with current literature about the low rate of achieving
lasting tumor remission among AIDS associated KS patients
[17,22]. Indeed, AIDS-associated KS is not a curable tumor
although durable remission or symptom relief may be reasonable
treatment goals.
A number of operational challenges surfaced during the conduct
of this research. As noted, many patients lacked CD4 count
information, were lost to follow-up, and had inconsistencies in
their chemotherapy regimens. These challenges point to structural
barriers, such as limited laboratory capacity, inconsistencies in
drug availability, and lack of transport to treatment centers. These
challenges are common in Malawi, as well as in other parts of sub
Saharan Africa [28–30] and have impacts on health outcomes.
Operational research can help identify bottlenecks and guide
implementation to improve delivery of chemotherapy among
patients receiving HIV care.
The rapid scale-up of cART over the last decade has led to
dramatic improvements in outcomes for HIV-infected patients in
resource-limited settings [31], including patients with KS.
Additionally, it is known that cART and chemotherapy have
treatment benefits over cART alone [32]. In spite of this
remarkable progress, there is still a great need for improved
management of AIDS-associated conditions, especially KS. Even
after cART scale-up, overall one-year mortality rates among KS
patients in Malawi are 22% in contrast to approximately 10%
among non-KS patients on cART [3]. These discrepancies point
to an urgent need for identification of appropriate regimens and
effective implementation.
Chemotherapy that effectively treats KS disease with minimal
side effects at a reasonable cost is a critical public health need in
sub Saharan Africa and other resource-constrained settings.
Bleomycin and vincristine administered together were shown to
be one such regimen in a routine clinical setting in Malawi.
Bleomycin/vincristine produced better treatment outcomes com-
pared to vincristine monotherapy without causing impairment in
CD4 count recovery. This finding needs to be confirmed in
observational and randomized settings and then considered by
policy makers.
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